Brittany A Potz1, Ashraf A Sabe1, Nassrene Y Elmadhun1, Sharif A Sabe1, Benedikt J V Braun1, Richard T Clements1, Anny Usheva1, Frank W Sellke2. 1. Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI. 2. Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI. Electronic address: fsellke@lifespan.org.
Abstract
BACKGROUND: Emerging data suggest a link between calpain activation and the enhanced inflammatory response of the cardiovascular system. We hypothesize that calpain activation associates with altered inflammatory protein expression in correlation with the proinflammatory profile of the myocardium. Our pig hypercholesterolemic model with chronic myocardial ischemia was treated with calpain inhibitors to establish their potential to improve cardiac function. METHODS: Yorkshire swine, fed a high cholesterol diet for 4 weeks then underwent placement of an ameroid constrictor on the left circumflex artery. Two weeks later, animals received either no drug (high-cholesterol control group, n = 8), a low dose of calpain inhibitors (0.12 mg/kg, n = 9), or a high dose of calpain inhibitors (0.25 mg/kg; n = 8). The high-cholesterol diet and calpain inhibitors were continued for 5 weeks, after which the pig was euthanized. The left ventricular myocardial tissue (ischemic and nonischemic) was harvested and analyzed for inflammatory protein expression. Data were statistically analyzed via the Kruskal-Wallis and Dunn post hoc test. RESULTS: Calpain inhibitor treatment coincides with increased expression of IKB-α and decreased expression of macrophages, NFkB, IL-1, and tumor necrosis factor (TNF)-α in the ischemic myocardial tissue as compared with the control group. An NFkB array revealed decreased expression of IRF5, JNK1/2, JNK2, CD18, NFkB p65, c-Rel, Sharpin, TNF R1, TNF R2, and DR5 in the ischemic myocardium of the group treated with a high dose of calpain inhibitors compared with the control. CONCLUSION: Calpain activation in metabolic syndrome is a potential contributor to cardiac dysfunction in metabolic disorders with ischemic background. We suggest that calpain inhibition downregulates NFkB signaling in the vessel walls, which might be useful for improving myocardial blood flow in ischemic conditions.
BACKGROUND: Emerging data suggest a link between calpain activation and the enhanced inflammatory response of the cardiovascular system. We hypothesize that calpain activation associates with altered inflammatory protein expression in correlation with the proinflammatory profile of the myocardium. Our pighypercholesterolemic model with chronic myocardial ischemia was treated with calpain inhibitors to establish their potential to improve cardiac function. METHODS: Yorkshire swine, fed a high cholesterol diet for 4 weeks then underwent placement of an ameroid constrictor on the left circumflex artery. Two weeks later, animals received either no drug (high-cholesterol control group, n = 8), a low dose of calpain inhibitors (0.12 mg/kg, n = 9), or a high dose of calpain inhibitors (0.25 mg/kg; n = 8). The high-cholesterol diet and calpain inhibitors were continued for 5 weeks, after which the pig was euthanized. The left ventricular myocardial tissue (ischemic and nonischemic) was harvested and analyzed for inflammatory protein expression. Data were statistically analyzed via the Kruskal-Wallis and Dunn post hoc test. RESULTS:Calpain inhibitor treatment coincides with increased expression of IKB-α and decreased expression of macrophages, NFkB, IL-1, and tumornecrosis factor (TNF)-α in the ischemic myocardial tissue as compared with the control group. An NFkB array revealed decreased expression of IRF5, JNK1/2, JNK2, CD18, NFkB p65, c-Rel, Sharpin, TNF R1, TNF R2, and DR5 in the ischemic myocardium of the group treated with a high dose of calpain inhibitors compared with the control. CONCLUSION: Calpain activation in metabolic syndrome is a potential contributor to cardiac dysfunction in metabolic disorders with ischemic background. We suggest that calpain inhibition downregulates NFkB signaling in the vessel walls, which might be useful for improving myocardial blood flow in ischemic conditions.
Authors: Ashraf A Sabe; Brittany A Potz; Nassrene Y Elmadhun; Yuhong Liu; Jun Feng; M Ruhul Abid; Jinnette D Abbott; Donald R Senger; Frank W Sellke Journal: J Thorac Cardiovasc Surg Date: 2015-09-03 Impact factor: 5.209
Authors: Shaista Malik; Nathan D Wong; Stanley S Franklin; Tripthi V Kamath; Gilbert J L'Italien; Jose R Pio; G Rhys Williams Journal: Circulation Date: 2004-08-23 Impact factor: 29.690
Authors: Annemarie Aarup; Tanja X Pedersen; Nanna Junker; Christina Christoffersen; Emil D Bartels; Marie Madsen; Carsten H Nielsen; Lars B Nielsen Journal: Arterioscler Thromb Vasc Biol Date: 2016-07-21 Impact factor: 8.311
Authors: Thomas S Anderson; Graham A Rance; Long Jiang; Matthew J Piggott; Elinor J Field; Guillaume P Chanoit Journal: PLoS One Date: 2018-11-15 Impact factor: 3.240
Authors: Laura A Scrimgeour; Brittany A Potz; Ahmad Aboul Gheit; Guangbin Shi; Melissa Stanley; Zhiqi Zhang; Neel R Sodha; Nagib Ahsan; M Ruhul Abid; Frank W Sellke Journal: J Am Heart Assoc Date: 2019-07-27 Impact factor: 5.501
Authors: Aicha Saadane; Yunpeng Du; Wallace B Thoreson; Masaru Miyagi; Emma M Lessieur; Jianying Kiser; Xiangyi Wen; Bruce A Berkowitz; Timothy S Kern Journal: Am J Pathol Date: 2021-06-29 Impact factor: 5.770